Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Patients with osteoporosis are at increased risk of suffering fractures due to a loss in bone strength. These fractures, in turn, place a considerable burden on public health systems. The osteoporosis therapy market is maturing, and treatment of the disease is associated with significant unmet need, particularly for therapies that are safer and more efficacious, especially those that can reduce the risk of nonvertebral fractures (e.g., hip fractures). The launch of several key therapies will lead to significant market changes over the 2017-2027 forecast period. In particular, Amgen/UCB/Astellas BioPharma’s romosozumab and Radius Health’s abaloparatide—in both subcutaneous(SC) and transdermal (TD) administration—will energize the market.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 19 country-specific interviews with experts.
Epidemiology: Osteopenia, osteoporosis, and total prevalent cases of FRAX high-risk.
Population segments in market forecast: Osteoporosis.
Emerging therapies: Registered: 1 drug; Phase II: 1 drug. Coverage of select preclinical and Phase I products.
Key drugs: Denosumab, teriparatide, abaloparatide SC, abaloparatide TD, alendronate, romosozumab, raloxifene
Already a Client? Log in to access this report.
David Rees, , is a Business Insights Analyst with the Cardiovascular, Metabolic, and Renal Disorders team at Decision Resources Group. Prior to joining Decision Resources Group, Dr. Rees was a Postdoctoral Research Associate at Imperial College London, and the Institute of Cancer Research. For his doctoral research, he studied the structures of molecular machines in the Nobel Prize winning laboratory of Prof. Sir John Walker at the University of Cambridge. Dr. Rees earned his undergraduate from the University of Bath.
Sunali Goonesekera is an Associate Epidemiologist at Decision Resources Group. Sunali holds a Master’s degree in Epidemiology from the Harvard School of Public Health and a in Biology (Honors) from Dartmouth College. Prior to joining Decision Resources Group, Sunali conducted epidemiological research and lead authored two manuscripts on racial/ethnic disparities in metabolic diseases at the New England Research Institutes. She has contributed to multiple publications in peer-reviewed journals in epidemiology and in the biological sciences.